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Quantitative sequence analysis of FBN1 premature termination
codons provides evidence for incomplete NMD in leukocytes
Abstract
We improved, evaluated, and used Sanger sequencing for quantification of single nucleotide
polymorphism (SNP) variants in transcripts and gDNA samples. This improved assay resulted in highly
reproducible relative allele frequencies (e.g., for a heterozygous gDNA 50.0+/-1.4%, and for a missense
mutation-bearing transcript 46.9+/-3.7%) with a lower detection limit of 3-9%. It provided excellent
accuracy and linear correlation between expected and observed relative allele frequencies. This
sequencing assay, which can also be used for the quantification of copy number variations (CNVs),
methylations, mosaicisms, and DNA pools, enabled us to analyze transcripts of the FBN1 gene in
fibroblasts and blood samples of patients with suspected Marfan syndrome not only qualitatively but
also quantitatively. We report a total of 18 novel and 19 known FBN1 sequence variants leading to a
premature termination codon (PTC), 26 of which we analyzed by quantitative sequencing both at gDNA
and cDNA levels. The relative amounts of PTC-containing FBN1 transcripts in fresh and
PAXgene-stabilized blood samples were significantly higher (33.0+/-3.9% to 80.0+/-7.2%) than those
detected in affected fibroblasts with inhibition of nonsense-mediated mRNA decay (NMD)
(11.0+/-2.1% to 25.0+/-1.8%), whereas in fibroblasts without NMD inhibition no mutant alleles could
be detected. These results provide evidence for incomplete NMD in leukocytes and have particular
importance for RNA-based analyses not only in FBN1 but also in other genes.
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Abstract 
We improved, evaluated, and used Sanger sequencing for quantification of SNP variants in 
transcripts and gDNA samples. This improved assay resulted in highly reproducible relative 
allele frequencies (e.g. for a heterozygous gDNA 50.0±1.4%, and for a missense mutation-
bearing transcript 46.9±3.7%) with a lower detection limit of 3-9%. It provided excellent 
accuracy and linear correlation between expected and observed relative allele frequencies. This 
sequencing assay, which can also be used for the quantification of CNVs, methylations, 
mosaicisms, and DNA pools, enabled us to analyze transcripts of the FBN1 gene in fibroblasts 
and blood samples of patients with suspected Marfan syndrome not only qualitatively but also 
quantitatively. We report a total of 18 novel and 19 known FBN1 sequence variants leading to a 
premature termination codon (PTC), 26 of which we analyzed by quantitative sequencing both at 
gDNA and cDNA levels. The relative amounts of PTC-containing FBN1 transcripts in fresh and 
PAXgene-stabilized blood samples were significantly higher (33.0±3.9% to 80.0±7.2%) than 
those detected in affected fibroblasts with inhibition of nonsense-mediated mRNA decay (NMD) 
(11.0±2.1% to 25.0±1.8%), while in fibroblasts without NMD inhibition no mutant alleles could 
be detected. These results provide evidence for incomplete NMD in leukocytes and have 
particular importance for RNA-based analyses not only in FBN1 but also in other genes. 
 
KEY WORDS: Marfan syndrome, fibrillin-1, nonsense mutation, nonsense-mediated mRNA decay, 
transcripts in blood, PAXgene blood system, quantitative sequencing UN
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Introduction 
Nonsense-mediated messenger RNA (mRNA) decay (NMD) is an evolutionary conserved 
quality control mechanism to detect a premature termination (nonsense) codon (PTC) and 
prevent the expression of truncated proteins [Maquat, 1995; Mühlemann et al., 2008]. In 
mammalian cells, NMD is triggered by a post-splicing exon-junction complex (EJC) of proteins 
which is downstream of a PTC and, hence, is not removed during translation. NMD consists of a 
series of steps that ultimately lead to the degradation of mRNA, resulting in functional 
haploinsufficiency [Wilkinson, 2005; Chang et al., 2007; Stalder and Mühlemann, 2008]. In 
contrast, transcripts containing a PTC near the initiation AUG codon or located downstream 
from the last ~55bp of the penultimate exon of a gene escape NMD, resulting in the synthesis of 
truncated proteins with different lengths that can be pathogenic through dominant-negative or 
gain-of-function effects [e.g. Inacio et al., 2004; Sanchez-Sanchez et al., 2007]. Consequently, 
NMD can not only prevent the accumulation of harmful proteins but can also modulate the 
clinical manifestations of genetic disorders, which has been reported by several previous studies 
[e.g. Dietz et al., 1993a; Karttunen et al., 1998; Frischmeyer and Dietz, 1999; Schrijver et al., 
2002; Khajavi et al., 2006; Mort et al., 2008]. 
Due to the preferentially degraded and thus often undetectable amount of the mutant transcript, 
NMD can also hamper the detection of heterozygous PTC mutations at the RNA level. This is 
often the case in molecular genetic testing because roughly one-third of all disease-causing 
mutations in humans induce premature termination of translation [e.g. Beroud et al., 2000; 
Mendell and Dietz, 2001]. In addition, RNA-based mutation detection is often hindered by the 
lack of appropriate samples, in which the NMD pathway can be pharmacologically inhibited 
prior to RNA extraction, e.g. by using translation-inhibiting drugs (anisomycin, cycloheximide, 
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6 
emetine, pactamycin, and puromycin) which increase the abundance of PTC-containing 
transcripts [Andreutti-Zaugg et al., 1997; Noensie and Dietz, 2001]. For these reasons, mutation 
screening is often performed at the genomic DNA (gDNA) level, rather than on RNA, even if 
RNA-based approaches allow efficient screening of the entire coding region of a large gene and 
permit identification of certain mutations undetectable by standard exon-by-exon gDNA 
screening. 
Nevertheless, there is an increasing need for the analysis of mRNA processing steps because 
such investigations are important to assess the pathogenic consequence of mutations identified at 
gDNA level. Indeed, there is a growing number of examples demonstrating that not only 
nonsense and frameshift, but also silent, missense, and in-frame mutations can result in PTC-
containing transcripts and that novel intronic sequence changes may have unpredictable effects 
on splicing, thus increasing the demand for mutation-oriented RNA analyses in the large number 
of sequence variants with unknown effect [Liu et al., 1997b; Caputi et al., 2002; Cartegni et al., 
2002]. Commercially available systems for RNA extraction from easily accessible blood 
samples, such as the PAXgene Blood RNA System (PreAnalytix; www.preanalytix.com), meet 
this increasing demand for transcript analyses. However, little is known about the efficiency of 
NMD in blood compared to tissues affected by the underlying disease. 
In this study, we address this issue by analyzing transcripts of the fibrillin-1 (FBN1; MIM# 
134797) gene from patients with suspected Marfan syndrome (MFS; MIM# 154700), an 
autosomal dominant connective tissue disorder, which displays variable manifestations in the 
cardiovascular, ocular, and skeletal systems and is caused by FBN1 mutations in the majority of 
cases [Dietz et al., 1991; De Paepe et al., 1996]. We report 18 novel and 19 known FBN1 
sequence variants leading to PTC, 26 of which we studied by improved quantitative sequencing 
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7 
both at the genomic and RNA levels. Comparative analysis of transcripts derived from affected 
primary dermal fibroblasts with and without NMD inhibition as well as from fresh and 
PAXgene-stabilized blood samples demonstrated tissue-specific degradation of PTC-containing 
FBN1 transcripts, providing evidence for incomplete NMD in white blood cells (leukocytes). 
The advantages and disadvantages of RNA analyses in leukocytes are discussed. 
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8 
Materials and Methods 
Patients and Detection of Mutations Leading to PTC 
We have performed FBN1 mutation analysis in nearly 400 unrelated patients with suspected 
MFS using our previously described mutation screening strategy [Mátyás et al., 2002a]. We have 
detected 135 FBN1 sequence variants, comprising missense (55%), nonsense (12%), and splice 
site mutations (18%) as well as small deletions (10%), insertions (1%), and insertion-deletions 
(4%), among which 37 were expected to introduce a PTC (Table 1). Sequence variant 
nomenclature follows the guidelines of the Human Genome Variation Society (HGVS, 
www.hgvs.org/mutnomen), with numbering using +1 as A of the ATG start codon of the FBN1 
mRNA reference sequences NM_000138.3. 
Data on the clinical phenotypes of patients were collected from medical records or during 
physical examinations by one of the authors (D.B., A.B., S.F., M.-C.A., T.C., and B.S.).  
 
Cell Culture 
Fibroblasts from skin biopsies were cultured in Minimal Essential Medium (MEM) with Earle's 
salts without L-glutamine (PAA Laboratories GmbH, Cölbe, Germany; www.paa.com) 
supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, Cölbe, Germany; 
www.paa.com), 1× antibiotic-antimycotic (Gibco, Invitrogen Corporation, Paisley, UK; 
www.invitrogen.com), and 2mM L-glutamine (LabForce AG, Nunningen, Switzerland; 
www.labforce.ch) and incubated at 37°C with 5% CO2. Prior to RNA extraction, each cell 
culture at ~100% confluence was split and one subculture (+CHX) was treated with the 
translation-inhibitor cycloheximide (Actidione; Sigma, St. Louis, MO; www.sigmaaldrich.com) 
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9 
for 6-8 hours at a concentration of 100µg/ml in order to inhibit NMD, while  to  one  subculture 
(-CHX) no cycloheximide was added. 
 
DNA and RNA Extraction 
Total DNA was extracted from fibroblasts and EDTA-anticoagulated whole blood samples by 
standard procedures or was referred to us for mutation detection in FBN1.  
Total RNA was isolated from both cycloheximide-treated and untreated fibroblast subcultures by 
using the RNeasy mini kit (Qiagen, Hilden, Germany; www.qiagen.com) and/or from PAXgene-
stabilized whole blood using the PAXgene blood RNA kit (Qiagen, Hilden, Germany; 
www.qiagen.com). For Patient BP, total RNA was also isolated by the RNeasy mini kit (Qiagen, 
Hilden, Germany; www.qiagen.com) from leukocytes derived immediately from EDTA-
anticoagulated whole blood (1 volume) after sample collection and lysis of erythrocytes for 
10min at 4°C by 8 volumes isoosmotic ammonium chloride solution (0.839% ammonium 
chloride, 0.1% potassium bicarbonate, and 0.004% EDTA-Na2). RNAs of Patients 101 and 344 
were treated with 2 units TURBO DNase (Ambion, Applied Biosystems, Rotkreuz, Switzerland; 
www.appliedbiosystems.com) in order to assess the effect of this treatment on quantitative 
sequencing. 
DNA and RNA concentrations were determined by using a NanoDrop ND-1000 system 
(NanoDrop Technologies, Wilmington, DE; www.nanodrop.com) according to the 
manufacturer’s instructions. RNA qualities (RNA integrity number, RIN) were assessed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA; www.agilent.com). RNA 
samples with RIN >4 were used as template for transcript analyses. 
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10 
Qualitative Transcript Analyses  
Prior to quantitative sequencing, qualitative transcript analysis was performed in order to 
investigate the effect of mutations on pre-mRNA splicing. Reverse transcription (RT)-PCR was 
used to amplify complementary DNA (cDNA) fragments containing a PTC-introducing 
mutation. RT-PCR was performed by means of the Qiagen OneStep RT-PCR kit (Qiagen, 
Hilden, Germany; www.qiagen.com) using 125ng total RNA and cDNA-specific primers 
flanking the respective mutation (Supp. Table S1) with the following cycling profile: 50°C for 
30min, 95°C for 15min, followed by 32-35 (fibroblast RNA) or 40 (blood RNA) cycles of 94°C 
for 30sec, annealing temperature (Supp. Table S1) for 45sec, and 72°C for 30sec, followed by a 
10min final extension step at 72°C. RT-PCR products (0.8-2.0µl) were purified using 0.1µl 
ExoSAP-IT (USB Corporation, Cleveland, OH; www.usbweb.com) in a total volume of 6µl by 
incubating at 37°C for 30min and at 80°C for 15min. Purified RT-PCR products were sequenced 
directly in both directions on an ABI PRISM 3100 or 3730 Genetic Analyzer with POP-6 or 
POP-7 polymer (ABI3100, ABI3730, POP6, POP7; Applied Biosystems, Rotkreuz, Switzerland; 
www.appliedbiosystems.com) using 0.8µM of primer, 1.5µl of 5× sequencing buffer, and 1µl of 
BigDye terminator v1.1 (Applied Biosystems, Rotkreuz, Switzerland; 
www.appliedbiosystems.com) in a final reaction volume of 10µl and subsequently purified using 
Sephadex G-50 according to the manufacturer’s recommendations (Millipore Technical Note 
TN053; www.millipore.com). In order to detect transcripts of abnormal length, RT-PCR 
products were also separated and visualized by standard gel electrophoresis using ethidium 
bromide-containing 1.5% agarose gels for 1-2 hours at 7.7V/cm. All thermal cycles were run on 
a MJ Research PTC-200 thermocycler (MJ Research Inc., Waltham, MA; 
www.mjresearch.com). 
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Improvement of Quantitative Sequencing 
In a preliminary study, we performed a series of tests to improve a previously described 
quantification of single nucleotide polymorphisms (SNPs) by automated DNA sequencing [Qiu 
et al., 2003]. In repeated (5×) experiments, we tested factors thought to be involved in the 
reproducibility and accuracy of quantitative sequencing. Experiments using gDNA samples of 
heterozygous individuals (C/T, C/A, G/A, and G/T) or gDNA pools with different wild-type to 
mutant allele frequencies (G/A, C/T) showed that 1) the number of PCR cycles (25, 32, 35, and 
40) had, surprisingly, no impact on quantitative sequencing if 2) the amount of PCR templates 
was high enough to generate real-time PCR threshold cycle (Ct) values less than 30; 3) there was 
no significant difference between the DNA polymerases tested (HotStarTaq, Qiagen, Hilden, 
Germany; www.qiagen.com vs. HOT FIREPol, Solis Biodyne, Tartu, Estonia; www.sbd.ee); 4) 
for real-time PCR, 10× SYBR Green I buffer (SYBR Green PCR Core Reagents, P/N 4304886, 
Applied Biosystems, Rotkreuz, Switzerland; www.appliedbiosystems.com) was superior at 
0.25× rather than at 1×, 0.5×, or 0.125× final concentration, also in comparison with 1× ready to 
use SYBR Green PCR Master Mix (P/N 4309155, Applied Biosystems, Foster City, CA); 5) 
ExoSAP-IT (USB Corporation, Cleveland, OH; www.usbweb.com) PCR purification resulted in 
more reproducible quantification results than column-based purification (QIAquick, Qiagen, 
Hilden, Germany; www.qiagen.com) or amplicons without purification; 6) sequences and 
positions of PCR and sequencing primers had no impact on quantitative sequencing if 7) peak 
heights in raw data chromatograms reached at least ~1000 relative fluorescence units (RFU) but 
were below the detection maximum of ~8000RFU on an ABI3100 and if 8) raw data or the KB 
basecaller and corresponding mobility files were used instead of the original ABI basecaller and 
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12 
mobility files; 9) for the highest reproducibility the same capillary, polymer, and sequencing 
instrument should be used during the whole procedure of quantitative sequencing (POP6, POP7, 
ABI3730, and two different ABI3100 were tested). In addition, one-step RT-PCR experiments 
resulted in more reproducible transcript ratios than two-step protocols, also enabling the usage of 
the same reaction mix for both gDNA with known and RNA with unknown allele ratios. 
Using the most reproducible conditions (Ct <30, nonoverloaded raw data >1000RFU, and KB 
basecaller or raw data), we tested the accuracy of our improved quantitative sequencing by 
analyzing 1) gDNA samples of patients with Charcot-Marie-Tooth disease type 1A (CMT1A) 
who carry an additional copy (duplication) of the PMP22 gene and thus harbor the SNP 
c.*59A>C (NM_000304.2; rs13422 dbSNP build 129) in a natural ratio of 2:1 (66.7% vs. 
33.3%); 2) four different gDNA pools with expected wild-type to mutant allele frequencies of 
1.5:1, 2:1, 3:1, and 5:1 prepared by diluting the heterozygous mutant gDNA using homozygous 
wild-type gDNA as diluent (performed for two G>A substitutions in the FBN1 exons 33 and 53); 
as well as 3) FBN1 transcripts harboring single nucleotide substitutions (c.1875T>C, 
c.4621C>T) previously tested by our SNuPE-ONCE assay at cDNA level [Mátyás et al., 2002b]. 
 
Improved Quantitative Sequencing of Mutant Transcripts 
Our quantitative sequencing approach consists of three main steps, namely 1) determination of 
correction factors (for correction of unequal detection of the two alleles) which are derived from 
samples with known allele ratio, 2) peak height measurement of samples with unknown allele 
ratio, and 3) calculation of the relative amount of mutant allele using the corresponding 
correction factor.  
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13 
Accordingly, for the determination of correction factors, gDNAs of patients heterozygous for an 
investigated mutation (A>B) were amplified in duplicate and each amplicon was sequenced four 
times in both directions, making sure that raw sequence signals are higher than 1000RFU but not 
overloaded. Peak heights (A50, B50) were obtained either from raw or analyzed data using 
Sequence Analysis Software v3.7/5.1/5.2 (Applied Biosystems, Rotkreuz, Switzerland; 
www.appliedbiosystems.com) and the corresponding KB basecaller v1.1/1.2. For raw sequence 
data, allele-specific peak heights were calculated by subtracting the lowest RFU (i.e. baseline 
signal) from the maximum RFU of the corresponding nucleotide base. For KB analyzed data, 
allele specific peak heights were determined by direct peak height measurements. Subsequently, 
correction factor (k) was calculated for each sequencing direction as an average of simple ratios 
of peak heights (A50/B50). Similarly, for the analysis of transcripts with unknown allele ratio, one-
step RT-PCRs were performed in triplicate, each amplicon was sequenced four times in both 
directions, and peak heights (AX, BX) were obtained as measured at the gDNA level for known 
allele ratios. For the assessment of unknown allele ratios, mutant peak heights (BX) were 
normalized by the corresponding correction factor (k*BX) and the relative amount of the mutant 
allele (XB) was estimated as an average of XB=k*BX/(AX+k*BX) calculated for each sequencing 
direction. For the arithmetic mean of replicates (n=4 for gDNA and n=6 for cDNA), upper and 
lower confidence limits were calculated using critical values of paired t-test distribution.  
All RT-PCR thermal cycles were run on an ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems, Rotkreuz, Switzerland; www.appliedbiosystems.com) without 9600 
emulation but with dissociation stage and using 10× SYBR Green I buffer (SYBR Green PCR 
Core Reagents, P/N 4304886, Applied Biosystems, Rotkreuz, Switzerland; 
www.appliedbiosystems.com) at 0.25× final concentration, in order to assure Ct values less than 
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14 
30. RT-PCR purification, cycle sequencing reaction/purification as well as RT-PCR product 
quality controls were performed as described above for qualitative transcript analyses. 
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15 
Results 
Reproducibility and Accuracy of Quantitative Sequencing 
Quantitative sequencing resulted in highly reproducible relative allele frequencies (e.g. for 
heterozygotes 50.0±1.4%, P=0.05; Table 2) if (real-time) PCR generated Ct values <30, raw 
sequence signals were high enough but not overloaded, and, most importantly, KB basecaller or 
raw sequence data was used for peak height measurement. Indeed, in contrast to the original ABI 
basecaller, raw sequence data and the KB basecaller provided highly reproducible results, 
independent of the start and end points used for sequence analysis. The lower detection limit of 
quantitative sequencing ranged from 3% to 9% depending on the heights of background signals 
(Figure 1).  
The quantitative sequence analyses of PMP22 gene duplication and gDNA pools with four 
different wild-type to mutant allele ratios provided excellent accuracy (e.g. for PMP22 
duplication 66.6±2.2%, P=0.05; Table 2) and linear correlation (Pearson’s correlation coefficient 
R>0.99, data not shown) between expected and observed relative allele frequencies, respectively. 
Our SNuPE-ONCE and quantitative sequencing assays revealed comparable accuracies (Table 
2). In contrast to SNuPE-ONCE, however, quantitative sequencing needs only primers and 
chemistries used for mutation detection in routine sequencing, making it superior for 
quantification of relative allele frequencies of >10%.  
 
Qualitative Transcript Analyses 
Since not only intronic but also exonic mutations can affect FBN1 pre-mRNA splicing, e.g. by 
disrupting exonic splicing enhancer (ESE) sequences by the mechanism called nonsense-
mediated alternative splicing (NAS) leading to exon skipping or aberrant  splicing  [c.f.  Caputi 
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16 
et al., 2002], we performed qualitative transcript analyses for all 26 patients for which 
cycloheximide-treated fibroblast cell lines and/or PAXgene-stabilized blood samples were 
available (Table 1). Qualitative sequencing and fragment length analysis of PTC-introducing 
exonic mutations revealed no aberrant splicing, although mutant transcripts were clearly 
detectable by sequencing. The three intronic nucleotide changes (Patients 59, 46, 46B, and 204) 
resulted in different splicing defects. While c.247+1G>A (Patient 59) led to skipping of the 
entire exon 2, c.347-2A>G (Patients 46 and 46B) introduced a novel acceptor splice site and thus 
inserted one nucleotide (G) from intron 3 into the open reading frame (Table 1). Similarly, 
c.6379+6T>G (Patient 204) created a novel donor splice site, extending exon 51 by five 
nucleotides of intron 51 (Table 1). The splicing defects of c.247+1G>A and c.347-2A>G were 
identical both in cycloheximide-treated fibroblasts and PAXgene blood samples, while the effect 
of c.6379+6T>G could be analyzed only in fibroblasts. All three intronic mutations introduced 
new reading frames ending in a PTC. 
 
Quantitative Analysis of PTC-containing Transcripts  
In cycloheximide-untreated fibroblasts, quantitative sequencing revealed no mutant transcripts, 
i.e. mutant alleles were below the detection limit of the assay (Figure 1). In cycloheximide-
treated fibroblasts, however, quantitative sequencing clearly detected PTC-containing transcripts 
with relative frequencies ranging, likely according to treatment efficiencies and cell responses, 
from 11.0±2.1% to 25.0±1.8% (P=0.05; Figure 1). As expected, cycloheximide treatment did not 
change significantly the level of transcripts harboring the missense mutation c.4454G>A 
(p.C1485Y) used as control in this study (Figure 1). These results highly suggest the translation-
dependent degradation of PTC-containing FBN1 transcripts in fibroblasts.  
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17 
In contrast, in PAXgene-stabilized blood samples quantitative sequencing demonstrated a high 
relative amount of PTC-containing FBN1 transcripts ranging from 33.0±3.9% to 80.0±7.2% 
(P=0.05), suggesting that NMD is incomplete in leukocytes (Figures 2, 3B, and 4). Intra-
individual (Figures 3A and 4), inter-individual (Figure 3C), and intra-familial (Figure 3C) 
differences in the corresponding relative mutant transcript levels were statistically not significant 
in the majority of cases, indicating the impact of the quantitative transcript analysis of a single 
PAXgene-stabilized blood sample. DNase treatment did not significantly influence the results of 
quantitative sequencing (data not shown). Similarly, comparative analysis of PAXgene and fresh 
EDTA blood samples demonstrated comparable relative amounts of PTC-bearing transcripts 
ranging from 40.0±4.0% to 47.0±7.1% (P=0.05; Figures 4A and B), suggesting that the 
stabilizing solution used in the PAXgene tubes does not interfere with the NMD machinery and 
thus does not influence the interpretation of our results.  
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Discussion 
In the post-genome era, not only the detection and scoring of SNPs is important but also their 
quantification at both the gDNA and cDNA levels. Available technologies for SNP 
quantification, such as real-time PCR, pyrosequencing, single-base extension assays, MLPA, 
microarrays, and massive parallel sequencing, however, have variable sensitivity and may need 
special equipment, chemistry, and/or assay design [e.g. Goossens et al., 2009]. For this reason, 
Sanger DNA sequencing using dye terminator chemistry on standard sequencing machines has 
been suggested as a fast and cost-effective single-tube method for SNP quantification, taking 
advantage of the fact that the peak height of a particular nucleotide base is proportional to the 
template amount present in the reaction [e.g. Nurpeisov et al.,  2003;  Qiu  et al.,  2003;  Anjos  
et al., 2004; Lewin et al., 2004]. However, one major problem with non-real-time-PCR-based 
assays such as sequencing is to choose the number of thermal cycles and the amount of templates 
in PCR suitable for quantification. Our method described here can overcome this limitation by a 
single real-time amplification using SYBR Green I, allowing the characterization of PCR prior to 
sequencing. Using correction factors, KB basecaller, and identical conditions for both the 
determination of correction factors and the measurement of unknown allele ratios, our approach 
circumvents further drawbacks of previous studies, enabling reproducible and accurate 
quantification of SNP variants. Consequently, our method can be used not only for transcript 
analyses, as demonstrated here, but also for quantitative analysis of copy number variations, 
proportion of methylation, mosaicisms, and DNA pools.  
Using our improved sequencing assay for quantitative analysis of a large cohort of PTC-
introducing FBN1 mutations, we found high levels of mutant transcripts in leukocytes whereas 
mutant transcripts were undetectable in untreated fibroblasts. Although we have not investigated 
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19 
NMD directly, this finding highly suggests tissue-specific degradation of PTC-containing FBN1 
transcripts by NMD. This conclusion is in accordance with a previous study which showed that 
NMD of COL10A1 nonsense mutations causing Schmid-type metaphyseal chondrodysplasia is 
complete in cartilage chondrocytes but incomplete in non-cartilage lymphoblastoid cell lines and 
bone-derived osteoblast cultures [Bateman et al., 2003]. A difference in NMD has also been 
previously observed between blood samples and lymphoblastoid cell lines of the same patients, 
demonstrating high levels of PTC-bearing OPA1 transcripts in RNA obtained from blood (40-
50%) in comparison with that from lymphoblastoid cell lines (20-30%) [Schimpf et al., 2008]. In 
addition, inter-tissue (CVS-stromal cells, amniocytes, and lymphocytes) and inter-individual 
variation in NMD efficiency has been reported for PTCs in different genes, such as DMD and 
ESCO2 [Kerr et al., 2001; Resta et al., 2006]. Further evidence has recently been provided for 
variable NMD efficiency among cells, suggesting that NMD is an inherent character of each cell 
[Linde et al., 2007]. 
One explanation for this variability in the efficiency of NMD may be tissue- and/or cell-type-
specific expression and interaction of NMD factors, such as UPF1, UPF2, and UPF3, and 
components of the exon-junction complex (EJC), such as eIF4A3, Y14, MAGOH, and RNPS1. 
Indeed, different NMD routes have been specified by distinct EJC components, in which low 
abundance of RNPS1 has been associated with low NMD efficiency [e.g. Gehring et al., 2005; 
Chan et al., 2007; Viegas et al., 2007]. Thus, it might be possible, for example, that the 
expression of the RNPS1 gene is more abundant in fibroblasts leading to intensive degradation of 
PTC-bearing FBN1 transcripts. Furthermore, the presence of different NMD routes in blood and 
fibroblasts cannot be excluded due to lack of reports on tissue-specific variation of NMD routes. 
Alternatively, it is possible that FBN1 transcripts are present at such a low level that it is under 
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the detection limit of the NMD machinery. This hypothesis is consistent with our observation 
that the total amount of FBN1 transcripts in blood is ~1000 times lower than that expressed in 
fibroblasts (data not shown). Similarly, since the 5’ end of the FBN1 gene consists of three 
alternatively spliced exons as well as sequences with different promoter activity [Corson et al., 
1993; Biery et al., 1999; Guo et al., 2007], one could speculate that FBN1 transcripts in blood 
use other regulatory sequences generating an alternative open reading frame resistant to NMD. 
However, we could not explain incomplete NMD in blood by in silico six-frame translation of 
the entire known coding sequence of FBN1 (data not shown). In addition, the variation in the 
relative amounts of mutant alleles observed in this study may not only be due to variation in 
NMD but also to differences in the expression of both mutant and normal FBN1 alleles [cf. 
Hutchinson et al., 2003]. Further studies are necessary to clarify these possibilities. 
Moreover, in this study we also extended the number of disease-causing FBN1 mutations by 
identifying 18 novel PTC-introducing sequence variants. By demonstrating the true effect of  
PTC mutations in fibroblasts that trigger the NMD quality control pathway, the mutations 
identified here can serve as a basis for genotype-phenotype studies [cf. Faivre et al., 2007, 2009], 
emphasizing the role of functional haploinsufficiency in the molecular pathogenesis of MFS [cf. 
Mátyás et al., 2007]. Although several studies have previously investigated the expression of 
FBN1 transcripts in fibroblasts [e.g. Dietz et al., 1993a, 1993b;  Hewett  et al.,  1994;  Halliday  
et al., 1999; Schrijver et al., 2002], this work describes the first comparative transcript analysis of 
PTC-introducing FBN1 mutations in whole blood and fibroblast cells. Our finding that PTC-
bearing transcripts are clearly detectable in PAXgene blood samples seems to be neither 
restricted to FBN1 nor universally valid (Table 3). This may also be true for lymphoblastoid cell 
lines, albeit with lower PTC transcript levels as discussed above, since incomplete NMD has 
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been observed also in such cells investigating PTC-containing transcripts of the genes OPA1, 
BRCA1, and APC [Gismondi et al., 1998; Perrin-Vidoz et al., 2002; Schimpf et al., 2008]. 
However, it remains unknown whether incomplete NMD occurs with comparable levels of PTC 
transcripts in all types of leukocytes. 
Finally, incomplete NMD has consequences for molecular genetic testing. Incomplete NMD can 
allow RNA-based mutation detection in blood, offering efficient screening of the exons of large 
genes as well as identification of aberrant splicing caused by intronic sequence variants 
undetectable by standard exon-by-exon gDNA screening. However, routine RNA-based 
mutation screening in blood may be hampered by low gene expression and RNA quality (RIN 5-
7) as well as by relatively short RT-PCR product lengths (400-500 bp), as is the case for FBN1. 
In addition, while PTC mutations and splicing defects may be clearly detected, no correct 
conclusion is possible on mutant transcript expression and NMD in other (affected) tissues by 
analyzing RNA from blood samples. Furthermore, for some genes (e.g. COL3A1) RT-PCR may 
fail or results in unspecific products both in PAXgene blood and lymphoblastoid cells (data not 
shown), making transcript analyses in such samples difficult or impossible.  Consequently,  the  
a priori possibility of incomplete NMD and/or mutation detection should be considered in 
transcript analyses for each gene, PTC mutation, and tissue. 
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Figure legends 
FIGURE 1. Quantitative sequence analysis of premature termination codon (PTC)-containing 
FBN1 transcripts in fibroblasts. The relative amounts of mutant alleles are given with respect to 
the total heights of corresponding electrophoretic peaks normalized by the appropriate correction 
factor derived from gDNA (black bars). Mutant transcripts from cycloheximide-untreated (bars 
with diagonal lines) and cycloheximide-treated (white bars) fibroblasts are indicated. Note that in 
all untreated fibroblasts the relative amounts of mutant alleles were below the detection limit of 
the assay (ND, not detectable, the highest level of background signals are given in parentheses). 
The FBN1 missense mutation c.4454G>A (p.C1485Y) was used as control. Error bars indicate 
95% confidence intervals. Arrows denote patients from whom PAXgene-stabilized blood sample 
was also taken for further investigations (see Figure 3B). 
FIGURE 2. Quantitative sequence analysis of PTC-containing FBN1 transcripts in PAXgene-
stabilized blood samples, showing high levels of mutant transcripts (light-gray bars). Arrows 
denote patients from whom a second PAXgene-stabilized blood sample was investigated (see 
Figure 3A); other labels are as used in Figure 1. 
FIGURE 3. Variation in mutant transcript levels among different probes, tissues, and 
individuals. A: Quantitative sequence analysis of PTC-containing FBN1 transcripts in two 
sequentially taken PAXgene-stabilized blood samples. B: Transcript levels in two sequentially 
taken PAXgene blood samples and fibroblasts. C: Transcripts of the same mutation in related 
(Patients 46 and 46B, 36 and 36B) and unrelated (Patients 55, 288, 326, and 376) individuals. 
Transcript levels of the second PAXgene blood samples are indicated by dark-gray bars, other 
labels are as used in Figures 1 and 2. 
UN
CO
RR
EC
TE
D 
AC
CE
PT
ED
 A
RT
IC
LE
Published 2008 by W
iley-Liss, Inc. 
 
  
1
Supporting Information available from the editorial office (humu@wiley.com) upon request. 
UNCORRECTED ACCEPTED ARTICLE 
 
M
utation Update 
 
 
 
 
 
 
 
Human M
utations 
 
 
 
 
 
 
 
 
 
DOI 10.1002/humu.20952 
 
Transglutaminase-1 (TGM1) Gene M
utations in Autosomal Recessive Congenital 
Ichthyosis: Summary of M
utations (Including 23 Novel) and M
odeling of TGase-1  
 
Matthew L. Herman 1, Sharifeh Farasat 1, Peter J. Steinbach 2, Ming-Hui W
ei 1, 3, Ousmane Toure 1, 
Philip Fleckman 4, Patrick Blake 1, 5, Sherri J. Bale 6, Jorge R. Toro 1 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD  
20892, USA 
2Center for Molecular Modeling, Division of Computational Bioscience, Center for Information 
Technology, NIH, Bethesda, MD, 20892, USA 
3B
sic Research Program, SAIC-Frederick Inc., Frederick, MD  21702, USA 
4Division of Dermatology, Department of Medicine, University of W
ashington, Seattle, W
A, 
98195, USA  
5Howard Hughes Medical Institute, Chevy Chase, MD  
6GeneDx, Inc, Gaithersburg, MD  20877, USA 
 
†This article is a US government work and, as such, is in the public domain in the United 
States of America. 
Received 27 Sep  2008; revised 27 Oct 2008; accepted 17 Nov 2008 
 
 
33 
FIGURE 4. Quantitative sequencing exemplified by analysis of the FBN1 nonsense mutation 
c.4621C>T (p.R1541X). A: Representative partial forward sequence of the region flanking 
c.4621C>T (arrowed). Sequences on gDNA with known relative mutant allele frequency of 50% 
were used to calculate the correction factor (k), which is the simple ratio of peak heights of the 
wild-type C (blue) and mutant T (red) bases, allowing the determination of unknown allele ratios 
at cDNA level. Fibroblasts were treated (+CHX) or untreated (-CHX) by cycloheximide prior to 
RNA extraction. Leukocyte RNA was extracted from four PAXgene-stabilized blood samples 
(PAXgene 1A and 1B taken in 2004, PAXgene 2A and 2B taken in 2007) and two fresh EDTA 
blood samples (EDTA 2A and 2B taken in 2007). B: Results of repeated quantitative sequencing 
of cDNAs derived from blood samples as exemplified in Figure 4A. Note that different blood 
samples and RNA extraction methods result in no significant difference in the relative amounts 
of mutant transcript. Error bars indicate 95% confidence intervals. 
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TABLE 1. PTC-introducing FBN1 mutations identified in this study 
Patient Sequence variantd 
 Year  Phenotypec     
#a 
of 
birth 
Materia
lb SS OS CS FH 
Disord
r Location Nucleotide change AA change Reference 
211 1973 BP (+) - + + MFS Exon 2 c.229G>T p.G77X This study 
59 1960 BP, F + ? (+) - MFS* Intron 2 c.247+1G>A (c.165_247del) p.P56HfsX45 [Dietz et al., 
1993a] 
46 1966 BP, F + - + + MFS Intron 3 c.347-2A>G (c.346_347insG) p.I116SfsX13 This study 
46B 1993 BP (+) - ? + MFS Intron 3 c.347-2A>G (c.346_347insG)† p.I116SfsX13† This study 
18 1990 NA + - + + MFS Exon 5 c.508delT p.Y170TfsX20 [Baumgartner et 
al., 2005] 
21 1977 NA + - + - MFS* Exon 6 c.651G>A p.W217X [Baumgartner et 
al., 2005] 
257 1982 NA ? ? ? ? MFS** Exon 8 c.917delA p.N306TfsX24 This study 
16 1997 F + - + - MFS Exon 10 c.1206delT p.P404HfsX44 [Baumgartner et 
al., 2005] 
337 1974 F + + + - MFS Exon 10 c.1285C>T p.R429X [Mátyás et al., 
2002a] 
47 1963 F + (+) + - MFS Exon 12 c.1522delC p.Q508RfsX71 This study 
36 1961 BP, F + - + - MFS Exon 12 c.1546C>T p.R516X [Arbustini et al., 
2005] 
36B 1995 BP  + - (+) + MFS Exon 12 c.1546C>T† p.R516X† [Arbustini et al., 
2005] 
372 1963 NA + - + + MFS Exon 13 c.1693C>T p.R565X [Quan et al., 1995] 
55 1971 F + - + + MFS Exon 15 c.1904_1919del p.Y635SfsX78 [Rommel et al., 
2002] 
326 1975 F + + + - MFS Exon 15 c.1904_1919del§ p.Y635SfsX78§ [Rommel et al., 
2002] 
305 1965 NA + (+) + + MFS Exon 15 c.1905C>G p.Y635X This study 
262 1995 NA (+) - + - MFS* Exon 16 c.1981dupT p.C661LfsX20 This study 
233 1983 NA + - + + MFS Exon 17 c.2122C>T p.Q708X This study 
443 2001 NA + - - - MFS* Exon 21 c.2581C>T p.R861X [Liu et al., 1997a] 
249 1991 NA + ? + ? MFS Exon 23 c.2763T>A p.C921X This study 
KF 1981 NA (+) - + + MFS Exon 25 c.3191_3194delAAGA p.E1065GfsX22 [Baumgartner et 
al., 2005] 
162B 1948 NA - - + + MFS* Exon 27 c.3373C>T p.R1125X [Rommel et al., 
2005] 
185 1957 F ? ? ? ? MFS** Exon 27 c.3373C>T§ p.R1125X§ [Rommel et al., 
2005] 
98 1956 F - + + ? MFS Exon 28 c.3513C>A p.C1171X This study 
61 1936 F + - + + MFS Exon 28 c.3568_3578del p.P1190IfsX4 This study 
13 1986 F + ? (+) - MFS* Exon 35 c.4451delA p.N1484TfsX5 This study 
BP 1965 BP,BE, 
F 
+ - + + MFS Exon 37 c.4621C>T p.R1541X [Halliday et al., 
1999] 
1 1975 BP + - (+) ? MFS* Exon 38 c.4786C>T p.R1596X [Loeys et al., 
2001] 
62 1961 NA + + + ? MFS Exon 38 c.4786C>T§ p.R1596X§ [Loeys et al., 
2001] 
30 1987 NA + ? (+) ? MFS* Exon 41 c.5143delA p.T1715PfsX17
8 
This study 
291 1976 BP + - (+) ? MFS* Exon 41 c.5157_5158insGG p.C1720GfsX1
74 
This study 
63B 1979 NA + - - + MFS* Exon 43 c.5368C>T p.R1790X [Arbustini et al., 
2005] 
101 1960 BP, F + - + ? MFS Exon 43 c.5368C>T§ p.R1790X§ [Arbustini et al., 
2005] 
280 1983 BP, F (+) - + - MFS* Exon 48 c.5924_5925dupAT p.E1976MfsX5 This study 
204 1987 F ? ? ? ? MFS** Intron 51 c.6379+6T>G 
(c.6379_6380insGTCAG) 
p.D2127GfsX3
5 
This study 
56 1970 F + - + - MFS* Exon 57 c.7039_7040delAT p.M2347VfsX1
9 
[Körkkö et al., 
2002] 
281 1997 BP  + - + - MFS Exon 57 c.7063dupA p.R2355KfsX1
2 
This study 
288 1966 BP + - + + MFS Exon 58 c.7240C>T p.R2414X [Körkkö et al., 
2002] 
376 1969 BP (+) + (+) + MFS* Exon 58 c.7240C>T§ p.R2414X§ [Körkkö et al., 
2002] 
139 1988 NA + - + - MFS Exon 61 c.7605C>A p.C2535X [Palz et al., 2000] 
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317 1993 NA (+) - (+) - MFS* Exon 62 c.7800C>A p.Y2600X This study 
2B 1960 NA + + + ? MFS Exon 62 c.7801C>T p.Q2601X [Baumgartner et 
al., 2005] 
161 1963 NA + + + + MFS Exon 62 c.7801C>T§ p.Q2601X§ [Baumgartner et 
al., 2005] 
344 1992 BP (+) - - ? MFS* Exon 63 c.7977C>A p.C2659X This study 
455 1994 NA + - + ? MFS Exon 65 c.8525_8529delTTAAC p.L2842PfsX7 [Palz et al., 2000] 
a Coded designations (two-letter code or numbers).  
b Material for transcript analysis: BP, RNA extracted from PAXgene-stabilized whole blood; BE, 
RNA extracted from EDTA-anticoagulated whole blood; F, RNA extracted from primary dermal 
fibroblasts; NA, material not available for transcript analysis. 
c Patients indicated by MFS fulfilled the diagnostic criteria for Marfan syndrome [De Paepe et 
al., 1996], those by MFS* only partially. MFS** indicates patients with suspected Marfan 
syndrome without clinical details. SS, skeletal system; OS, ocular system; CS, cardiovascular 
system; FH, family history; +, affected; (+), slightly affected; -, not affected; ?, lack of 
information. 
d Sequence variants are described in relation to the translation initiation site of the mRNA 
reference sequence NM_000138.3. Mutation numbering is after HGVS and journal standards, 
with +1 as the A of the ATG initiation codon. Recurrent mutations in related (†) and unrelated 
(§) patients are marked. 
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TABLE 2. Reproducibility and accuracy of the improved quantitative sequencing assay 
exemplified by different allele ratios and templates 
 
Patient Gene Mutation Template Expected allele ratio (%) Allele ratio (%) observed by quantitative sequencing (CI) 
24108 PMP22 c.*59A>C (3’UTR) gDNA 50.0 : 50.0a 50.0 : 50.0 (±1.4) 
22564 PMP22 c.*59A>C (3’UTR) gDNA 66.7 : 33.3a 66.6 : 33.4 (±2.2) 
BP FBN1 c.4621C>T (p.R1541X) cDNAb 70.7 : 29.3c 71.8 : 28.2 (±2.7)d 
RB FBN1 c.1875T>C (p.N625N) cDNA 50.3 : 49.7c 46.9 : 53.1 (±3.7) 
 
a Patient 24108 is heterozygous for c.*59A>C and thus represents a natural 1:1 (50.0% vs. 50.0%) DNA pool of 
normal and mutant PMP22 alleles (NM_000304.2; rs13422 dbSNP build 129). Patient 22564 is affected by the 
Charcot-Marie-Tooth disease type 1A (CMT1A) and thus carries an additional copy (duplication) of the PMP22 
gene, harboring c.*59A>C in a natural ratio of 2:1 (66.7% vs. 33.3%). 
b Cells were treated with cycloheximide prior to RNA extraction. 
c Allele ratios previously determined by using the SNuPE-ONCE assay [Mátyás et al., 2002b]. 
d Prior to quantitative sequencing, RT-PCR product was column purified using the QIAquick PCR purification kit as 
used also for the SNuPE-ONCE assay [Mátyás et al., 2002b]. 
CI, 95% confidence interval. 
 
UN
CO
RR
EC
TE
D 
AC
CE
PT
ED
 A
RT
IC
LE
Published 2008 by W
iley-Liss, Inc. 
 
  
1
Supporting Information available from the editorial office (humu@wiley.com) upon request. 
UNCORRECTED ACCEPTED ARTICLE 
 
M
utation Update 
 
 
 
 
 
 
 
Human M
utations 
 
 
 
 
 
 
 
 
 
DOI 10.1002/humu.20952 
 
Transglutaminase-1 (TGM1) Gene M
utations in Autosomal Recessive Congenital 
Ichthyosis: Summary of M
utations (Including 23 Novel) and M
odeling of TGase-1  
 
Matthew L. Herman 1, Sharifeh Farasat 1, Peter J. Steinbach 2, Ming-Hui W
ei 1, 3, Ousmane Toure 1, 
Philip Fleckman 4, Patrick Blake 1, 5, Sherri J. Bale 6, Jorge R. Toro 1 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD  
20892, USA 
2Center for Molecular Modeling, Division of Computational Bioscience, Center for Information 
Technology, NIH, Bethesda, MD, 20892, USA 
3Basic Research Program, SAIC-Frederick Inc., Frederick, MD  21702, USA 
4Division of Dermatology, Department of Medicine, University of W
ashington, Seattle, W
A, 
98195, USA  
5Howard Hughes Medical Institute, Chevy Chase, MD  
6GeneDx, Inc, Gaithersburg, MD  20877, USA 
 
†This article is a US government work and, as such, is in the public domain in the United 
States of America. 
Received 27 Sep  2008; revised 27 Oct 2008; accepted 17 Nov 2008 
 
 
37 
TABLE 3. Expression of PTC-containing transcripts of different genes previously determined in 
PAXgene-stabilized blood 
 
Gene PTC   
Symbol Name Exons Position Expression (based on)  Reference 
DSG2 Desmoglein 2 15  Exon 13 ~30-40% (agarose gel)  [Pilichou et al., 2006] 
OPA1 Optic atrophy 1 30  Exons 11, 15, 
20, 21, 25, 27 
20-40% (pyrosequencing)  [Schimpf et al., 2008] 
MLH1 MutL homolog 1, colon cancer, 
nonpolyposis type 2  
19  Exon 14 <10% (agarose gel)  [Wehner et al., 2005] 
DFNB59 Deafness, autosomal recessive 59 7  Exon 4 ~30% (agarose gel)  [Collin et al., 2007] 
LMNA Lamin A 12  Exon 8 ~20-30% (agarose gel)  [Morel et al., 2006] 
SGCE Sarcoglycan, epsilon 11  Exon 6 ~40-50% (agarose gel)  [Misbahuddin et al., 2007]
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